This study is testing a new drug called MBRC-101, which is an antibody-drug conjugate (a targeted therapy that delivers a powerful drug directly to cancer cells). It's for people with advanced solid tumors that haven't responded to standard treatments. The main goals are to see if MBRC-101 is safe, how it moves through the body, and if it shows early signs of shrinking tumors. Researchers will also look at how long people live, how long their disease is controlled, and if their tumors shrink or disappear. You can join if you are 18 or older and have advanced cancer that hasn't responded to other treatments. The study is currently unclear on its recruitment status.

Study design

This is a first-in-human, open-label study with different phases (Phase 1, 1b, and 2) and plans to enroll about 130 participants. It's designed to find the best dose and then test the drug's effectiveness.

What's involved

You will need to provide written consent and be able to follow all study procedures. The study will monitor for side effects for up to 24 months, and dose-limiting toxicities will be evaluated over 21 days.

Compensation

Not stated in the trial record.

Follow-up

Safety will be monitored for up to 24 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.